Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen TAVNEOS (avacopan by Year
TAVNEOS (avacopan — ANCA-Associated Vasculitis) — Worldwide product sales ($M) ($M)
Amgen TAVNEOS (avacopan: $459M in FY2025, up 62.2% from a year earlier.
Where the FY2025 figure comes from
“|| TAVNEOS ® | 423 | 36 | 459 | 283 | 62%”
Source: Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | TAVNEOS (avacopan — ANCA-Associated Vasculitis) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 459 | +62.2% | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 283 | +111.2% | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 134 | +538.1% | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
| FY2022 | Dec 31, 2022 | 21 | – | Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗ |
Breakdown
What makes up TAVNEOS (avacopan
- TAVNEOS (avacopan — ANCA-Associated Vasculitis) — U.S. product sales ($M)423 · FY2025
- TAVNEOS (avacopan — ANCA-Associated Vasculitis) — Rest of World (ROW) product sales ($M)36 · FY2025
- TAVNEOS (avacopan — ANCA-Associated Vasculitis) — Worldwide reported sales growth YoY (%)62.0% · FY2025
- TAVNEOS (avacopan — ANCA-Associated Vasculitis) — Worldwide volume growth YoY (%)–
Cite this data
StockData. (2026). Amgen TAVNEOS (avacopan ($M), annual FY2022–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-tavneos-ww
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.